Cost-effectiveness of sotorasib versus adagrasib in previously treated <i>KRAS</i> G12C-mutated advanced NSCLC: a US healthcare payer perspective
Sotorasib was more cost-effective than adagrasib in the second- and subsequent-line treatment of <i>KRAS</i> G12C NSCLC, based on current efficacy and safety data.
Authors
- David Michael Waterhouse (ORCID: https://orcid.org/0000-0001-5589-9939)
- Simon Jones
- Nadia Karim
- Björn Stollenwerk
Institutions
- Amgen (United States) (US)
- Health Economics and Outcomes Research (United Kingdom) (GB)
- Oncology Hematology Care (US)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2025-12-18
- DOI
- https://doi.org/10.1080/13696998.2025.2604968
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00